The Exchange Bet That Broke the Wrong Way: CYH's Disenrolled Patients Came Back as Self-Pay

Guidance cut as the ACA enhanced-tax-credit expiry flips from a modeled $20-30M EBITDA headwind to a real $50-75M one

CYH · Earnings Call · 2026-07-23

The exchange bet that broke the wrong way

Midway through 2026, Community Health Systems has been doing everything right on the controllables — paying down debt, completing divestitures, holding cost growth near zero. But the second quarter shows the macro moving against it in exactly the way management had argued it wouldn't. Adjusted EBITDA fell to $330M from $380M a year ago on a 9.8% net revenue decline, and full-year guidance was cut from a $1.415 billion midpoint to $1.3–$1.375 billion. The problem isn't volume — same-store adjusted admissions rose 2.9%. It's who is showing up.

For the full year, just to clarify for everyone, we had initially estimated that the net revenue impact from HIX disenrollment would be between $90 million and $110 million, and the Adjusted EBITDA impact would be between $20 million and $30 million.
Jason Johnson, Executive Vice President and Chief Financial Officer · 2026-07-23

That was the February model: patients losing enhanced premium-tax-credit coverage would largely stay out of the system, so EBITDA would fall only modestly with lost revenue. The company now puts the EBITDA impact at $50M–$75M annually — roughly double. The assumption broke in reverse: the increase in uninsured arrivals didn't come from a population staying home; it came from exchange members continuing to use the ER. Self-pay visits, ~5% of last year's mix, are now just over 6%.

Who the uninsured are — and why the model can't absorb it

The FY26 exchange economics inverted. CFO Jason Johnson, asked what gives him confidence the headwind doesn't worsen through Q4, conceded the correlation: “in the second quarter, we saw a more significant decline in our HIX volumes, and it was obviously a correlation with our increase in self-pay.” — Jason Johnson, Executive Vice President and Chief Financial Officer · 2026-07-23 The company has "no complete visibility" into plan shifting, he added, but “we are seeing more business in the <keyword id="c4bb6e6047">bronze plan</keyword> this year than we have in the past” — Kevin Hammons, Chief Executive Officer · 2026-07-23 — high-deductible products that functionally behave like self-pay for collection purposes. On collection rates, the answer was stark: “we only collect a few pennies on the dollar anyway, so there's no real room to get much worse.” — Kevin Hammons, Chief Executive Officer · 2026-07-23 Gas prices are now framed as the binding constraint. CYH's median household income across its communities is $64,000 versus the $81,000 national average, so pump-price spikes are a direct tax on discretionary care. The consumer-confidence read-through is visible in the mix: same-store inpatient surgeries fell 3.8%, orthopedics the largest decliner, as patients deflect into imaging and clinic visits that don't convert to procedures — a deferral dynamic tied to significant decline in elective cases. The contrast with prior guidance is the key. On the February call, Jason defended the $20–30M EBITDA assumption: “we started by applying what our normal 12% EBITDA margin, but then recognizing that there's some fixed costs that remain, we ticked that up to more of the $20 million to $30 million range.” — Jason Johnson, Executive VP and Chief Financial Officer · 2026-02-19 By April he was still waiting for data — “it's still going to be second or third quarter before we get a better feel for that.” — Jason Johnson, Executive Vice President and Chief Financial Officer · 2026-04-22 Now the data is in, and it runs the opposite of the plan: these patients are not disappearing, they're migrating to uncompensated care.

Costs under control — which makes the mix problem uglier

The controllables are genuinely working: same-store operating expense per adjusted admission rose just 0.3%, contract labor is down 5.6%, hourly rates up 1.1%, and supply expense fell to 14.2% of revenue. The leak is concentrated — medical specialty fees up roughly 19% (anesthesia subsidies tied to lower surgical volumes, plus radiology) — spread over a fixed cost base absorbing more self-pay. That shows up in the cash flow. Free cash flow turned deeply negative as AR days climbed; management blames payers "auditing more claims before they pay," but the strain is real at 1.3x interest coverage and 107% liabilities-to-assets — effective net cash around -$8.5B. Even the offset is a coin flip: newly approved Medicaid state-directed payments (Florida, Indiana, Georgia) added roughly $40–45M to the quarter, but the Florida 2026 plan year hasn't been submitted to CMS, so guidance's range depends on whether it's recognized at all. For a company at 6.7x leverage, that's a wide band. For a stock down ~95% from its 2015 peak and off 22.8% from its 2026 high in the last 90 days, this is the kind of miss that re-prices before the balance-sheet work catches up.